Lanean...
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH an...
Gorde:
| Argitaratua izan da: | Front Immunol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5702627/ https://ncbi.nlm.nih.gov/pubmed/29213270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01603 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|